ADA 2020: US Pivotal Trial Data Support Medtronic’s Next-Gen Insulin Pump

18 Jun 2020

Clinical data presented during the virtual ADA meeting show Medtronic’s MinMed 780G hybrid closed-loop insulin system, an upgraded version of the company's 770G system, improved patients’ ability to keep their blood-glucose levels within target range.

Molecular model of insulin molecule, 3D illustration — 3D model of an insulin molecule

New 90-day results from the US pivotal trial of Medtronic PLC's MiniMed 780G insulin pump show the next-generation system safely improves users’ “time in range” (70-180 mg/dL) – the percentage of time the users’ blood glucose is near the optimal level – without increasing hypoglycemia.

Primary investigator Anders Carlson of the Park Nicollet International Diabetes Center in Minneapolis presented results from the US pivotal...